Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.6 EUR | +3.58% | -0.39% | -2.32% |
04-29 | DRAEGERWERK : Hauck & Aufhauser reiterates its Buy rating | ZD |
04-25 | Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's attractive earnings multiples are brought to light by a P/E ratio at 10.57 for the current year.
- The company shows low valuation levels, with an enterprise value at 0.3 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.32% | 906M | B+ | ||
+8.69% | 219B | B | ||
+6.69% | 183B | B- | ||
+10.90% | 133B | B- | ||
+25.41% | 108B | A- | ||
+0.27% | 63.06B | A- | ||
+12.72% | 52.02B | B+ | ||
+3.96% | 48.2B | B+ | ||
+0.40% | 40.37B | A | ||
+15.03% | 39.35B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRW3 Stock
- Ratings Drägerwerk AG & Co. KGaA